Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16425
|
| Title: | Therapeutic strategies of denosumab sequential therapy: A four-armed multi-institutional randomized controlled trial |
| Authors: | F, SH;L, CC;H, CC;L, CY;Y, HK;W, CY |
| Contributors: | National Center for Geriatrics and Welfare Research |
| Abstract: | Objective: Denosumab, a RANKL inhibitor, is renowned for its long-term efficacy in improving BMD and reducing fracture risks. However, its discontinuation leads to a rapid rebound and BMD loss, necessitating effective follow-up interventions. This study aimed to evaluate four treatment regimens post-denosumab discontinuation in patients with osteoporosis. Methods: The 2-y, multicenter, randomized controlled trial involved 101 postmenopausal women and men who had received biannual denosumab treatments for at least 2 y. The patients were randomized into four groups continued denosumab, zoledronate followed by denosumab, zoledronate for 2 y, and zoledronate followed by a supervised drug holiday. The primary outcome was the percent change from baseline at 24 months in BMD at various sites. Results: An alternating regimen of denosumab and zoledronate could lead to a BMD enhancement (LS-BMD, 2.25%; IQR, 0.02–5.82%). A strategically timed zoledronate injection can maintain BMD for two years post-denosumab (BMD at the lumbar spine [LS-BMD], -0.71%; interquartile range [IQR], − 3.67% to 2.69%). However, a single zoledronate dose post-denosumab brings significant BMD loss (LS-BMD, − 2.76%; IQR, − 6.12% to 2.06%). Conclusion: The study highlighted the "catch-up effect" in BMD upon resuming denosumab after a break, suggesting a potential reset in the body's response. Despite limitations like the short follow-up duration, the study provides novel insights into managing bone health post-denosumab discontinuation. Future studies should aim to validate the long-term therapeutic effect and the safety of the alternative regimen. |
| Date: | 2024-08-20 |
| Relation: | Aging Clinical and Experimental Research. 2024 Aug 20;36:S265. |
| Link to: | http://dx.doi.org/10.1007/s40520-024-02766-y |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001363175502220 |
| Appears in Collections: | [王貞予] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001363175502220.pdf | | 182Kb | Adobe PDF | 20 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
